<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01731444</url>
  </required_header>
  <id_info>
    <org_study_id>PhenylephrineRCT</org_study_id>
    <nct_id>NCT01731444</nct_id>
  </id_info>
  <brief_title>Phenylephrine Tumescence for Hemostasis in Surgery for Burn Injury</brief_title>
  <official_title>Phenylephrine Tumescence for Hemostasis in Surgery for Burn Injury - A Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Manitoba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Manitoba</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The standard of care for treatment of burn injury is to inject a solution of epinephrine
      under the skin of the injured site in order to reduce blood loss during skin grafting. This
      solution of epinephrine has been shown to have effects on the body outside the donor site.
      Some people have increases in heart rate and blood pressure. We will study the effect of a
      phenylephrine solution in place of an epinephrine solution to control blood loss. We think
      that phenylephrine will help decrease blood loss and not change blood pressure or heart rate.

      The injured area will be injected under the skin and a skin graft will be taken in the same
      way as we usually do. The only change will be the use of phenylephrine in the solution
      instead of epinephrine.

      Our goal is to find whether or not phenylephrine or epinephrine solution results in a
      reduction of blood loss without affecting the rest of the body.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2014</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean arterial blood pressure (MAP)</measure>
    <time_frame>during first 30 minutes</time_frame>
    <description>Mean arterial blood pressure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>q15 min</time_frame>
    <description>Cut off for safety: Diastolic &gt;140 or Systolic &gt;180;
Recorded:
just prior to induction of anesthesia
maximum heart rate during time of procedure
minimum heart rate during time of procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>q15 min</time_frame>
    <description>Recorded:
just prior to induction of anesthesia
maximum heart rate during time of procedure
minimum heart rate during time of procedure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Blood Loss, Surgical</condition>
  <arm_group>
    <arm_group_label>Phenylephrine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 ug/cc</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epinephrine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1:1000000</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenylephrine</intervention_name>
    <arm_group_label>Phenylephrine</arm_group_label>
    <arm_group_label>Epinephrine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        a) Burn injury requiring debridement and grafting between 5-30% TBSA

        Exclusion Criteria

          1. Head and neck, hand, foot, or genital burns

          2. On anticoagulants (except NSAIDs)

          3. On monoamine oxidase inhibitor or tricyclic antidepressant

          4. Coronary or peripheral vascular disease

          5. History of arrhythmias

          6. On a Beta-blocker

          7. History of vascular abnormality

          8. Hypertension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Justin Gawaziuk, MSc</last_name>
    <phone>2047873669</phone>
    <email>jgawaziuk@hsc.mb.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1R9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Justin P Gawaziuk, MSc</last_name>
      <phone>2047873669</phone>
      <email>jgawaziuk@hsc.mb.ca</email>
    </contact>
    <investigator>
      <last_name>Sarvesh Logsetty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2012</study_first_submitted>
  <study_first_submitted_qc>November 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2012</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>blood loss</keyword>
  <keyword>burn</keyword>
  <keyword>hemostasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Burns</mesh_term>
    <mesh_term>Blood Loss, Surgical</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
    <mesh_term>Hemostatics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

